Sun Pharma can touch Rs 900, says Vijay Chopra

Vijay Chopra of enochventures.com told CNBC-TV18, "Sun Pharmaceutical Industries is a company which is well placed to reap on the benefits of the future, number one. Number two, the US Food and Drug Administration (FDA) which happened earlier to which we saw a lot of pressure on this stock, more or less, it has been digested into the stock price. Another point, the stock has very beautifully consolidated around levels of Rs 650-700 and I think that Rs 700 is a level that once it crosses, I see a level of Rs 900 coming on the stock. So, the rise is in store for the stock. ""The entire pharmaceutical pack is consolidating and it has more or less bottomed out. So, we will see in the coming few quarters that pharmaceutical companies performing very well and Sun Pharma, as I said, is well placed to reap on the benefits of the same, so Rs 900 is a target which I would like to recommend on Sun Pharma," he added.